The invention relates to a method for predicting the response to the treatment with an antitumor agent of a patient suffering lung cancer based on the expression levels in a sample of said patient of the AEG-1 gene or of the combination of the AEG-1 and BRCA1 genes wherein low expression levels of AEG-1 or low expression levels of AEG-1 and BRCA1 are indicative of a positive response of the patient to said antitumor agent.